DiaMedica Therapeutics Inc. (DMAC) Price Target Analysis
Updated Jun 18, 2026
Analyst Rating: Buy
Based on 6 analysts42.4% Below Target
DMAC trades 42.4% below Wall Street's consensus target of $8.33.
Current Price$5.85
Average Target$8.33
Target
Current
Low$7.00
Median$8.00
High$10.00
Analyst Target Range
Forward P/E—
PEG Ratio—
Implied Growth-20.1%
(Declining)
Analyst Spread36.0%
(Moderate)
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Consensus Scenario Assumptions
The base valuation assumes DMAC achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 6 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
DMAC Price Target Analysis
Updated June 22, 2026As of June 22, 2026, DiaMedica Therapeutics Inc. (DMAC) has a Wall Street consensus price target of $8.33, based on estimates from 6 covering analysts. With the stock currently trading at $5.85, this represents a potential upside of +42.4%. The company has a market capitalization of $315M.
Analyst price targets range from a low of $7.00 to a high of $10.00, representing a 36% spread in expectations. The median target of $8.00 aligns closely with the consensus average.
The current analyst consensus rating is Buy, with 6 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, DMAC trades at a trailing P/E of -8.4x. Analysts expect EPS to grow -20.1% over the next year.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside
+57.8%
Industry Consensus
Avg Forward P/E
32.7x
(Growth Premium)
Peers with Coverage
8 / 10
Active Analyst Tracking
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 ATHAAthira Pharma, Inc. | $17M | $4.34 | — | — | — | — | — |
 ACMRACM Research, Inc. | $7.3B | $109.87 | $100.00 | -9.0% | Buy | 55.2x | 10 |
 NERVMinerva Neurosciences, Inc. | $31M | $4.47 | $5.00 | +11.9% | Buy | — | 7 |
 ANIKAnika Therapeutics, Inc. | $193M | $14.42 | — | — | Buy | — | 6 |
 PRAXPraxis Precision Medicines, Inc. | $8.2B | $282.31 | $584.00 | +106.9% | Buy | — | 16 |
 BIIBBiogen Inc. | $29.0B | $196.58 | $218.32 | +11.1% | Buy | 13.5x | 48 |
 ACADACADIA Pharmaceuticals Inc. | $3.7B | $21.62 | $33.67 | +55.7% | Buy | 55.6x | 37 |
 INVAInnoviva, Inc. | $1.7B | $22.49 | $37.00 | +64.5% | Buy | 6.3x | 10 |
 RAREUltragenyx Pharmaceutical Inc. | $2.7B | $27.44 | $48.36 | +76.2% | Buy | — | 33 |
 NKTRNektar Therapeutics | $1.2B | $60.98 | $149.60 | +145.3% | Buy | — | 33 |
DMAC — Frequently Asked Questions
Quick answers to the most common questions about buying DMAC stock.
What is the DMAC stock price target for 2026?
The consensus Wall Street price target for DMAC is $8.33, representing 42.4% upside from the current price of $5.85. With 6 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
Is DMAC a buy, sell, or hold?
DMAC has a consensus rating of "Buy" based on 6 Wall Street analysts. The rating breakdown is predominantly bullish, with 6 Buy/Strong Buy ratings. The consensus 12-month price target of $8.33 implies 42.4% upside from current levels.
Is DMAC stock overvalued or undervalued?
DMAC's current price is $5.85 with a consensus target of $8.33 (42.4% implied move). Analyst estimates suggest the stock is undervalued at current levels.
How high can DMAC stock go?
The most bullish Wall Street analyst has a price target of $10 for DMAC, while the most conservative target is $7. The consensus of $8.33 represents the median expectation. These targets typically reflect 12-month expectations.
How many analysts cover DMAC stock?
DMAC is moderately covered, with 6 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 6 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the DMAC stock forecast?
The 12-month DMAC stock forecast based on 6 Wall Street analysts shows a consensus price target of $8.33, with estimates ranging from $7 (bear case) to $10 (bull case). The median consensus rating is "Buy".
Should I buy DMAC stock?
Wall Street analysts are very optimistic on DMAC, with a "Buy" consensus rating and $8.33 price target (42.4% upside). 6 of 6 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do DMAC price targets vary so much?
DMAC analyst price targets range from $7 to $10, a 36% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $8.33 consensus represents the middle ground.
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare